Novartis Expands U.S. Manufacturing with NC Facility

0:00Farma Powerhouse Novartis just dropped news on a fresh manufacturing spot in Morrisville, North Carolina. They're building a 56,200 square foot facility to crank out active ingredients for solid dose tablets, capsules, and even RNA therapies. This move ramps up their U.S. drug production game from raw materials to finish meds. It's their seventh new site announced in the last year, all under a massive $23 billion push into American manufacturing and R&D. With this one, they'll run five facilities across three spots in the state, locking in more local control over supply chains. Leaders like CEO Vasnar Simhan say it's about building connected operations to develop, make, and shipments right here at home for U.S. patients. North Carolina is turning into their key home, especially after breaking ground last December on a big flagship plan for oncology, immunology, and more. The Morrisville setup will back today's drugs and tomorrow's breakthroughs like advanced RNA treatments.

1:04It fits their 2025 pledge to produce all major U.S. meds domestically, with similar expansions popping up in California, Texas, Florida, Indiana, and New Jersey. All this investment means faster access to cutting-edge therapies, especially time-sensitive ones, like cancer drugs, keeping America ahead in the farmer race. Durham News today, powered by AI bringing U.A. matters.